Federal Circuit: Supplementation of aBLA Does Not Trigger New Notice of Commercial Marketing Obligations

Jul 7, 2020

Reading Time : 2 min

Genentech, Inc. and City of Hope (collectively, “Genentech”) manufacture and sell bevacizumab (Avastin), an antibody used to treat cancer. Immunex Rhode Island Corporation and Amgen, Inc. (collectively, “Amgen”) filed an abbreviated biologics license application under the BPCIA to market a biosimilar version of Avastin called Mvasi. After receiving FDA approval, on October 6, 2017, Amgen notified Genentech of its intent to commercially market Mvasi in at least 180 days, pursuant to 42 U.S.C. § 262(l)(8)(A).

Amgen later supplemented its Abbreviated Biologics License Application (aBLA) to add a manufacturing facility and modify the label for Mvasi. Despite these supplements, the drug product, Mvasi, did not change. By July 8, 2019, Amgen decided to commercially market Mvasi. Genentech filed an emergency motion and a motion for a temporary restraining order to preclude Amgen from entering the market. Genentech argued that Amgen’s supplemental applications created a distinct biological product licensed under Section 262(k), thus necessitating a new notice of commercial marketing and a renewed 180-day waiting period under Section 262(l)(8)(A). The district court denied both motions and this appeal followed.

On appeal, the Federal Circuit rejected Genentech’s argument that new disclosures relating to licensure (i.e., manufacturing facilities and labeling provisions) triggered a new notice requirement. The court observed that Section 262(l)(8)(A) relates to timing of notice for the biological product, whereas Section 262(k) pertains to licensure requirements. By its ordinary meaning, Section 262(l)(8)(A) requires that a biosimilar applicant provide notice to the reference product sponsor before commercially marketing a “biological product.” Section 262(k), on the other hand, sets for the contents that must be included to license the biosimilar product. Amgen’s supplemental applications submitted under Section 262(k) did not modify Mvasi—the biological product was the same. The Federal Circuit, therefore, declined to impose a requirement for a new notice of commercial marketing.

In reaching its decision, the court made clear that its interpretation was consistent with the Supreme Court’s decision in Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664 (2017). In Sandoz, the Court construed “licensed under subsection (k)” merely to require that the biological product was licensed by the date of commercial marketing. Further, Sandoz emphasized that Section 262(l)(8)(A) only includes one timing requirement, whereas Genentech’s interpretation could require notice each time a supplemental application was filed. Nothing in Section 262(l)(8)(A) turns on the characteristics of the biosimilar application or the merits of licensure. Thus, supplementing an aBLA with additional information does not trigger a requirement for a new notice of commercial marketing when the supplements are directed to the same biological product.

Practice Tip: The Federal Circuit noted that none of the supplemental applications at issue here changed the biological product. In most cases, changes to the biological product are likely to trigger a requirement for a separate original application. Thus, this case likely closes the door on the question of whether a supplemental application can ever trigger a new notice requirement. However, parties should still look to the specific nature of the supplemental application to determine whether the reasoning of this case can be distinguished.

Genentech, Inc. v. Immunex Rhode Island Corp., 2019-2115, 2020 WL 3635031 (Fed. Cir. Jul. 6, 2020)

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.